老年男性骨质疏松症治疗药物的决策树分析  

Decision Tree Analysis of Drugs in the Elderly Male Patients with Osteoporosis

作　　者：杨晨[1] 罗茂华[1] 黄海[1] 邓伟民[1] 

机构地区：[1]广州军区广州总医院药剂科,广州510010

出　　处：《中国药房》2015年第8期1009-1012,共4页China Pharmacy

基　　金：广东省中医药局科研课题(No.20141043)

摘　　要：目的:为医疗使用者提供临床参考,为医疗决策者提供数据支持。方法:收集我院2011年6-11月符合骨质疏松症诊断标准的老年男性患者99例作为研究对象,采用随机对照临床试验设计、单盲法,对补肾壮骨冲剂与阿仑膦酸钠片治疗老年男性骨质疏松症的有效性、安全性和经济学进行分析,连续临床观察6个月。选取有效率、成本、不良反应等指标构建决策树模型,并通过该模型计算出各组的用药期望成本与成本-效果比。结果:阿仑膦酸钠片期望效益较大。在成本增长5%或降低15%时,阿仑膦酸钠片组期望效益值均较大。结论:两种药物的药物经济学评价基本相同。OBJECTIVE：To provide reference for clinical medical users and data for medical decision-makers. METHODS：In total of 99 cases of elderly male patients with osteoporosis in our hospital were collected from Jun. to Nov. 2011. A randomized controlled clinical trial design and single blind method were used to analyze effectiveness,safety and economics of elderly male patients with osteoporosis treated with Busheng zhuanggu granule and alendronate sodium tablets through continuous clinical observation for 6 months. Indicators were selected to build a decision tree model,including efficiency rate,cost,adverse reactions and others,and expected costs and cost-effectiveness were calculated by the tree model in each group. RESULTS：Expected benefits of alendronate sodium tablets were greater. Expected benefits of Bushen zhuanggu granules were larger when cost increased by 5%,alendronate sodium tablets was still the greatest when cost was reduced by 15%. There were very small differences of the data between two groups of drugs. The data were nearly the same. CONCLUSIONS：Pharmacoeconomics evaluation of two drugs is basically the same.

关 键 词：药物经济学 决策树 骨质疏松症 补肾壮骨冲剂 阿仑膦酸钠片 

分 类 号：R956[医药卫生—药学] R681